1. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor–mutant lung adenocarcinomas with acquired resistance to kinase inhibitors;Balak;Clin. Cancer Res.,2006
2. C. Takimoto, E. Calvo, Principles of Oncologic Pharmacotherapy in Cancer Management: A Multidisciplinary Approach (Pazdur, R., Wagman, LD, Camphausen, KA, Hoskins WJ, eds), Cmp United Business Media, Manhasset, NY [Google Scholar], Cmp United Business Media, Manhasset, NY [Google Scholar], (2008), 10.1007/s11523-013-0258-9.
3. P. Calabresi, P.S. Schein, S.A. Rosenberg, Medical oncology: basic principles and clinical management of cancer, (1985). (1985), 10.1016/S0025-6196(12)61940-5.
4. C. Schettino, M.A. Bareschino, V. Ricci, F. Ciardiello, Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment, Expert review of respiratory medicine, 2 (2008) 167-178, 10.1586/17476348.2.2.167.
5. Production of micro asnd nano particles of pharmaceutical by supercritical carbon dioxide;Esfandiari;J. Supercritical Fluids,2015